BRPI1007443A2 - biomarcadores séricos e de urina associados à nefropatia diabética - Google Patents

biomarcadores séricos e de urina associados à nefropatia diabética

Info

Publication number
BRPI1007443A2
BRPI1007443A2 BRPI1007443A BRPI1007443A BRPI1007443A2 BR PI1007443 A2 BRPI1007443 A2 BR PI1007443A2 BR PI1007443 A BRPI1007443 A BR PI1007443A BR PI1007443 A BRPI1007443 A BR PI1007443A BR PI1007443 A2 BRPI1007443 A2 BR PI1007443A2
Authority
BR
Brazil
Prior art keywords
serum
diabetic nephropathy
biomarkers associated
urine biomarkers
urine
Prior art date
Application number
BRPI1007443A
Other languages
English (en)
Inventor
Li Hung-Yi
Chen Jin-Shuen
Ya-Ping Yeh Mary
Cheng Ping-Fu
Hsu Tsai-Wei
Tseng Tzu-Ling
Lin Wei-Ya
Li Yen-Peng
Chen Yi-Ting
Lin Yuh-Feng
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of BRPI1007443A2 publication Critical patent/BRPI1007443A2/pt
Publication of BRPI1007443B1 publication Critical patent/BRPI1007443B1/pt
Publication of BRPI1007443B8 publication Critical patent/BRPI1007443B8/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4728Details alpha-Glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121Serpins
    • G01N2333/8125Alpha-1-antitrypsin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BRPI1007443A 2009-01-28 2010-01-27 método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo BRPI1007443B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14777809P 2009-01-28 2009-01-28
US61/147,778 2009-01-28
PCT/CA2010/000097 WO2010085879A1 (en) 2009-01-28 2010-01-27 Urine and serum biomarkers associated with diabetic nephropathy

Publications (3)

Publication Number Publication Date
BRPI1007443A2 true BRPI1007443A2 (pt) 2017-09-12
BRPI1007443B1 BRPI1007443B1 (pt) 2020-10-13
BRPI1007443B8 BRPI1007443B8 (pt) 2021-07-27

Family

ID=42395076

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007443A BRPI1007443B8 (pt) 2009-01-28 2010-01-27 método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo

Country Status (14)

Country Link
US (4) US8465980B2 (pt)
EP (2) EP2623517B8 (pt)
JP (1) JP5689426B2 (pt)
CN (1) CN102300877B (pt)
BR (1) BRPI1007443B8 (pt)
CA (1) CA2748937C (pt)
DK (2) DK2391654T3 (pt)
ES (2) ES2552557T3 (pt)
HU (2) HUE025795T2 (pt)
MX (1) MX2011007811A (pt)
PL (2) PL2391654T3 (pt)
PT (2) PT2391654E (pt)
TW (1) TWI449910B (pt)
WO (1) WO2010085879A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia
CN103299192B (zh) * 2010-09-21 2016-05-11 普罗蒂阿米克斯国际有限公司 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
JP5714285B2 (ja) * 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
EP2592421B1 (en) * 2011-11-14 2017-08-30 Universitätsklinikum Jena Diagnosis of sepsis and systemic inflammatory response syndrome
JP2013178239A (ja) * 2012-01-31 2013-09-09 Ajinomoto Co Inc 早期腎症の評価方法、早期腎症評価装置、早期腎症評価方法、早期腎症評価プログラム、早期腎症評価システムおよび情報通信端末装置
WO2013122976A1 (en) * 2012-02-13 2013-08-22 New York University Osteopontin isoform a inhibitors and methods of use
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
CA2818328C (en) 2012-06-11 2017-09-05 Preventage Healthcare Llc Methods for improving diabetes management
EP3066476A2 (en) * 2013-11-04 2016-09-14 The Regents of the University of Michigan Biomarkers and methods for progression prediction for chronic kidney disease
CN103804484B (zh) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 一种网红细胞生长因子及其制备方法和应用
CN105572355B (zh) * 2015-03-13 2018-04-13 中国医学科学院肿瘤医院 检测食管癌的生物标志物
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
CN114487431A (zh) * 2020-11-12 2022-05-13 首都医科大学附属北京世纪坛医院 尿液α-2-HS-糖蛋白及其多肽片段在妊娠糖尿病中的应用
CN113687083B (zh) * 2021-08-20 2023-11-28 天津中医药大学 一种基于深度学习的糖尿病肾病早期预测方法及系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015904A1 (en) 1997-09-26 1999-04-01 University Of Washington Methods and compositions for diagnosing renal pathologies
JP2002090365A (ja) * 2000-02-08 2002-03-27 Internatl Reagents Corp 腎障害の検査手段
DE60029302T2 (de) * 2000-04-28 2007-08-09 Bayer Ag Diagnose von Leberfibrose mit Hilfe von Serummarkeralgorithmen
IL153206A0 (en) * 2000-06-13 2003-07-06 Childrens Medical Center Biosynthetic oncolytic molecules and uses therefor
DK1345969T3 (da) * 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
WO2003019193A1 (en) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
WO2004082617A2 (en) * 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20050266467A1 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006044666A2 (en) * 2004-10-15 2006-04-27 Northeastern University Detection of disease associated proteolysis by direct mass spectrometry analysis of low molecular weight peptides
DK1806359T3 (da) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
EP1946121A2 (en) * 2005-10-27 2008-07-23 Yale University, Inc. Urinary proteomic biomarker patterns in preeclampsia
US20070111245A1 (en) * 2005-11-09 2007-05-17 Ravi Thadhani Predicting diabetic nephropathy
WO2007110230A2 (en) * 2006-03-27 2007-10-04 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008092214A1 (en) 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
EP2479565A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia

Also Published As

Publication number Publication date
HUE025795T2 (en) 2016-05-30
EP2623517B8 (en) 2015-12-30
US20130252267A1 (en) 2013-09-26
JP2012516431A (ja) 2012-07-19
EP2391654B1 (en) 2015-09-09
DK2623517T3 (en) 2015-11-23
JP5689426B2 (ja) 2015-03-25
EP2623517A1 (en) 2013-08-07
CA2748937C (en) 2016-07-19
CN102300877B (zh) 2014-12-10
MX2011007811A (es) 2012-03-14
ES2552467T3 (es) 2015-11-30
US10101340B2 (en) 2018-10-16
ES2552557T3 (es) 2015-11-30
DK2391654T3 (en) 2015-11-16
EP2391654A4 (en) 2012-08-01
PT2623517E (pt) 2015-11-19
TWI449910B (zh) 2014-08-21
CN102300877A (zh) 2011-12-28
PT2391654E (pt) 2015-11-19
WO2010085879A1 (en) 2010-08-05
US20110086371A1 (en) 2011-04-14
BRPI1007443B1 (pt) 2020-10-13
EP2623517B1 (en) 2015-09-16
CA2748937A1 (en) 2010-08-05
TW201033616A (en) 2010-09-16
BRPI1007443B8 (pt) 2021-07-27
US8476077B2 (en) 2013-07-02
HUE025796T2 (hu) 2016-05-30
US8465980B2 (en) 2013-06-18
PL2623517T3 (pl) 2016-04-29
US20110079077A1 (en) 2011-04-07
PL2391654T3 (pl) 2016-04-29
EP2391654A1 (en) 2011-12-07
US20100197033A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
BRPI1007443A2 (pt) biomarcadores séricos e de urina associados à nefropatia diabética
BRPI0820557A2 (pt) biomarcadores diagnósticos de diabetes
IL233096A0 (en) Ratio based biomarkers and methods of use thereof
EP2443259A4 (en) BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF
FI20096188A0 (fi) Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
EP2370658A4 (en) DRILLING TIP WITH TROCAR TIP
BRPI1009269A2 (pt) biomarcadores de envelhecimento específicos do tecido.
BRPI0909948A2 (pt) alteração de células duplas em serviço otimizadas.
EP2438196A4 (en) REAGENTS AND RECOMBINASE POLYMERASE AMPLIFICATION KITS
EP2451600A4 (en) ARRANGEMENT OF A DOUBLE-SIDED INDEXABLE CUTTING INSERT AND A REINFORCEMENT ELEMENT
BRPI0920069A2 (pt) biomarcadores
WO2010036342A9 (en) Urinary biomarkers for predicting long-term dialysis
EP2089722A4 (en) BIOMARKERS
EP2265642A4 (en) BIOMARKERS
BRPI1006075A2 (pt) biomarcadores de cancer
BR112012008080A2 (pt) ensaios de rastreamento in vivo.
GB2474618B (en) Predictive biomarkers
EP2129285A4 (en) Analyte sensor
BR112012013418A2 (pt) marcador sérico bioquímico.
BRPI0820721A2 (pt) Reagentes e métodos para detectar analitos
BR112012008045A8 (pt) dispositivo de mancal intermediário com reforço de endentação para arranques
FI20095300A0 (fi) Kärkiosapipetti
EP2263086A4 (en) BIOMARKERS
FI20080247L (fi) Nupillinen pipetti
EP2265641A4 (en) BIOMARKERS

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: BIO PREVENTIVE MEDICINE CORPORATION (TW)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO